$CELG Company News
Why speculators see opportunity in younger, cyclical stocks 2:50 p.m. Dec. 26, 2014 - The Trading Deck
GoPro, Gilead Sciences, Celgene gain 11:28 a.m. Dec. 26, 2014 - MarketWatch
Dow ekes out gain for 37th record close of 2014 2:56 p.m. Dec. 24, 2014 - Anora Mahmudova
GoPro, Adamas climb, Cal-Maine slides 10:06 a.m. Dec. 24, 2014 - MarketWatch
Cal-Maine Foods shares fall on earnings miss 4:41 p.m. Dec. 23, 2014 - Wallace Witkowski
A teachable moment: Here are my worst stock picks of 2014 10:19 a.m. Dec. 23, 2014 - Jeff Reeves
Four signs that would indicate a new uptrend 2:52 p.m. Dec. 16, 2014 - The Trading Deck
Liquid growth stocks tell interesting tale 3:11 p.m. Dec. 9, 2014 - The Trading Deck
H&R Block shares fall on quarterly miss 6:42 p.m. Dec. 8, 2014 - Wallace Witkowski
The S&P 500 recorded its biggest drop in nearly 7 weeks 4:33 p.m. Dec. 8, 2014 - Anora Mahmudova
Celgene shares climb 1.9% 9:31 a.m. Dec. 8, 2014 - Sue Chang
Is the next Cisco out there? 3:24 p.m. Nov. 25, 2014 - The Trading Deck
5 charts show how stock repurchases boost prices 6:00 a.m. Nov. 18, 2014 - Ophir Gottlieb
The double-edged sword of growth-stock speculation 2:30 p.m. Nov. 14, 2014 - The Trading Deck
Two biotech leaders to watch 1:13 p.m. Oct. 28, 2014 - The Trading Deck
Celgene profit up 37%, raises outlook 7:42 a.m. Oct. 23, 2014 - MarketWatch.com
Be ready to play another market surge 11:25 a.m. Sept. 19, 2014 - The Trading Deck
14 stocks loved by top-performing fund managers 5:49 a.m. Sept. 18, 2014 - Philip van Doorn
Lululemon surges; RadioShack rebounds 2:24 p.m. Sept. 11, 2014 - Sue Chang
Major U.S. benchmarks rattle cage on first support 10:06 a.m. Sept. 10, 2014 - Michael Ashbaugh
IBD 50: Biotechs Hammered, Then Find Support 5:27 p.m. Dec. 26, 2014 - Investors Business Daily
Stock Market News for December 26, 2014 - Market News 10:10 a.m. Dec. 26, 2014 - Zacks.com
4 Biotech Stocks that Doubled in 2014 - Analyst Blog 9:00 a.m. Dec. 26, 2014 - Zacks.com
Celgene Corporation (CELG): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 7:00 a.m. Dec. 26, 2014 - Zacks.com
Biotech Stocks Take A Beating, But Find Support 3:56 p.m. Dec. 24, 2014 - Investors Business Daily
Stock Market News for December 24, 2014 - Market News 10:10 a.m. Dec. 24, 2014 - Zacks.com
Why I Expect The Biotech Sell-Off To Continue Into 2015 8:08 a.m. Dec. 24, 2014 - Seeking Alpha
Dow Tops 18000 7:50 p.m. Dec. 23, 2014 - The Wall Street Journal Interactive Edition
Seattle Genetics And Agios Pharmaceuticals: Opportunity Or Danger? 11:21 a.m. Dec. 23, 2014 - Seeking Alpha
Celgene (CELG) Weak On High Volume Today 10:02 a.m. Dec. 23, 2014 - TheStreet.com
RBC’s 5 Top Biotech Stocks to Buy for 2015 9:07 a.m. Dec. 23, 2014 - 247WallSt.com
5 Healthcare Stocks to Buy 4:04 a.m. Dec. 23, 2014 - InvestorPlace.com
Express Scripts Picks AbbVie HCV Drugs Over Gilead 4:59 p.m. Dec. 22, 2014 - Investors Business Daily
Celgene Gets Positive CHMP Recommendation for Revlimid - Analyst Blog 3:20 p.m. Dec. 22, 2014 - Zacks.com
Jim Cramer Answers Twitter (TWTR) Questions on Gilead, WhiteWave Foods, and More 1:37 p.m. Dec. 22, 2014 - TheStreet.com
Trade of the Day: IBB Up 40% YTD – Buy, Sell or Hold? 7:17 p.m. Dec. 21, 2014 - InvestorPlace.com
Juno Therapeutics IPO Hot As Cancer Curers In Demand 5:32 p.m. Dec. 19, 2014 - Investors Business Daily
Merrill Lynch Top Healthcare Stock Picks for 2015 2:00 p.m. Dec. 19, 2014 - 247WallSt.com
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo 10:53 a.m. Dec. 19, 2014 - Seeking Alpha
Cramer: ‘Downside’ to Biotech as ImmunoGen Stock Cut in Half 10:46 a.m. Dec. 19, 2014 - TheStreet.com
Critical Alerts For Invensense, FireEye, General Electric, Twitter and Celgene Released By InvestorsObserver 9:31 a.m. Dec. 22, 2014 - PR Newswire - PRF
Scanning Biotech Equities -- Celgene, Novavax, Amarin, Immunomedics, and Aeterna Zentaris 8:40 a.m. Dec. 17, 2014 - PR Newswire - PRF
Data Presented on REVLIMID® (lenalidomide) Compared with Investigators’ Choice in Relapsed/Refractory Diffuse Large B-Cell Lymphoma 8:34 p.m. Dec. 8, 2014 - BusinessWire - BZX
Additional Analyses of High-Risk Patients from Phase III Study (AML-001) OF Vidaza® (Azacitidine for Injection) in Acute Myeloid Leukemia Presented at ASH 8:33 p.m. Dec. 8, 2014 - BusinessWire - BZX
REVLIMID® (Lenalidomide) Single-Agent and Combination Studies in Mantle Cell Lymphoma (MCL) Presented at ASH 8:33 p.m. Dec. 8, 2014 - BusinessWire - BZX
New Data in Myelodysplastic Syndromes Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition 2:00 p.m. Dec. 8, 2014 - BusinessWire - BZX
Results from Phase III Study of REVLIMID® (Lenalidomide) Demonstrating Improved Transfusion Independence in Patients with Rare Blood Cancer, Non-Del-5Q Myelodysplastic Syndromes (MDS), Presented at ASH 1:49 p.m. Dec. 8, 2014 - BusinessWire - BZX
Age, Renal Impairment and Depth of Response Analyses of the FirstTM (MM-020/IFM 07-01)Study of Continuous REVLIMID® (lenalidomide) Plus Low-Dose dexamethasone in Newly-Diagnosed Multiple Myeloma Presented at ASH 9:58 p.m. Dec. 7, 2014 - BusinessWire - BZX
Critical Alerts For Noodles & Company, Goldcorp, YY, Celgene and LinkedIn Released By InvestorsObserver 9:31 a.m. Dec. 2, 2014 - PR Newswire - PRF
Celgene Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Corporation 4:30 p.m. Dec. 1, 2014 - BusinessWire - BZX
Celgene Receives Positive CHMP Opinion for OTEZLA® (apremilast), the First Oral PDE4 Inhibitor for the Treatment of Patients with Psoriasis and Psoriatic Arthritis 6:00 a.m. Nov. 21, 2014 - BusinessWire - BZX
Chef Michael Ferraro, the Pancreatic Cancer Action Network and Meals to Heal Team up with Celgene to Address Nutritional Needs and Challenges Faced by Pancreatic Cancer Patients and Caregivers 8:00 a.m. Nov. 20, 2014 - BusinessWire - BZX
UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Increases CD4 Counts in People Living With HIV 4:29 p.m. Nov. 19, 2014 - Marketwired
Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Counts in People Living With HIV 3:35 p.m. Nov. 19, 2014 - Marketwired
Oral OTEZLA® (Apremilast) Showed Sustained Clinical Response over Two Years in Patients with Active Psoriatic Arthritis 7:30 a.m. Nov. 18, 2014 - BusinessWire - BZX
Moffitt Cancer Center Announces Development of Experimental Treatment for Myelodysplastic Syndromes, Autoimmune Diseases 9:03 a.m. Nov. 17, 2014 - BusinessWire - BZX
Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene 9:10 a.m. Nov. 14, 2014 - PR Newswire - PRF
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo 8:50 a.m. Nov. 10, 2014 - PR Newswire - PRF
Critical Alerts For Alibaba, Bloomin' Brands, VoxelJet, 51job and Celgene Released By InvestorsObserver 9:31 a.m. Nov. 5, 2014 - PR Newswire - PRF
Celgene Corporation to Webcast at Upcoming Investor Conferences and Medical Congress 8:30 a.m. Oct. 31, 2014 - BusinessWire - BZX
Why speculators see opportunity in younger, cyclical stocks 2:50 p.m. Dec. 26, 2014 - The Trading Deck
GoPro, Gilead Sciences, Celgene gain 11:28 a.m. Dec. 26, 2014 - MarketWatch
Dow ekes out gain for 37th record close of 2014 2:56 p.m. Dec. 24, 2014 - Anora Mahmudova
GoPro, Adamas climb, Cal-Maine slides 10:06 a.m. Dec. 24, 2014 - MarketWatch
Cal-Maine Foods shares fall on earnings miss 4:41 p.m. Dec. 23, 2014 - Wallace Witkowski
A teachable moment: Here are my worst stock picks of 2014 10:19 a.m. Dec. 23, 2014 - Jeff Reeves
Four signs that would indicate a new uptrend 2:52 p.m. Dec. 16, 2014 - The Trading Deck
Liquid growth stocks tell interesting tale 3:11 p.m. Dec. 9, 2014 - The Trading Deck
H&R Block shares fall on quarterly miss 6:42 p.m. Dec. 8, 2014 - Wallace Witkowski
The S&P 500 recorded its biggest drop in nearly 7 weeks 4:33 p.m. Dec. 8, 2014 - Anora Mahmudova
Celgene shares climb 1.9% 9:31 a.m. Dec. 8, 2014 - Sue Chang
Is the next Cisco out there? 3:24 p.m. Nov. 25, 2014 - The Trading Deck
5 charts show how stock repurchases boost prices 6:00 a.m. Nov. 18, 2014 - Ophir Gottlieb
The double-edged sword of growth-stock speculation 2:30 p.m. Nov. 14, 2014 - The Trading Deck
Two biotech leaders to watch 1:13 p.m. Oct. 28, 2014 - The Trading Deck
Celgene profit up 37%, raises outlook 7:42 a.m. Oct. 23, 2014 - MarketWatch.com
Be ready to play another market surge 11:25 a.m. Sept. 19, 2014 - The Trading Deck
14 stocks loved by top-performing fund managers 5:49 a.m. Sept. 18, 2014 - Philip van Doorn
Lululemon surges; RadioShack rebounds 2:24 p.m. Sept. 11, 2014 - Sue Chang
Major U.S. benchmarks rattle cage on first support 10:06 a.m. Sept. 10, 2014 - Michael Ashbaugh
IBD 50: Biotechs Hammered, Then Find Support 5:27 p.m. Dec. 26, 2014 - Investors Business Daily
Stock Market News for December 26, 2014 - Market News 10:10 a.m. Dec. 26, 2014 - Zacks.com
4 Biotech Stocks that Doubled in 2014 - Analyst Blog 9:00 a.m. Dec. 26, 2014 - Zacks.com
Celgene Corporation (CELG): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 7:00 a.m. Dec. 26, 2014 - Zacks.com
Biotech Stocks Take A Beating, But Find Support 3:56 p.m. Dec. 24, 2014 - Investors Business Daily
Stock Market News for December 24, 2014 - Market News 10:10 a.m. Dec. 24, 2014 - Zacks.com
Why I Expect The Biotech Sell-Off To Continue Into 2015 8:08 a.m. Dec. 24, 2014 - Seeking Alpha
Dow Tops 18000 7:50 p.m. Dec. 23, 2014 - The Wall Street Journal Interactive Edition
Seattle Genetics And Agios Pharmaceuticals: Opportunity Or Danger? 11:21 a.m. Dec. 23, 2014 - Seeking Alpha
Celgene (CELG) Weak On High Volume Today 10:02 a.m. Dec. 23, 2014 - TheStreet.com
RBC’s 5 Top Biotech Stocks to Buy for 2015 9:07 a.m. Dec. 23, 2014 - 247WallSt.com
5 Healthcare Stocks to Buy 4:04 a.m. Dec. 23, 2014 - InvestorPlace.com
Express Scripts Picks AbbVie HCV Drugs Over Gilead 4:59 p.m. Dec. 22, 2014 - Investors Business Daily
Celgene Gets Positive CHMP Recommendation for Revlimid - Analyst Blog 3:20 p.m. Dec. 22, 2014 - Zacks.com
Jim Cramer Answers Twitter (TWTR) Questions on Gilead, WhiteWave Foods, and More 1:37 p.m. Dec. 22, 2014 - TheStreet.com
Trade of the Day: IBB Up 40% YTD – Buy, Sell or Hold? 7:17 p.m. Dec. 21, 2014 - InvestorPlace.com
Juno Therapeutics IPO Hot As Cancer Curers In Demand 5:32 p.m. Dec. 19, 2014 - Investors Business Daily
Merrill Lynch Top Healthcare Stock Picks for 2015 2:00 p.m. Dec. 19, 2014 - 247WallSt.com
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo 10:53 a.m. Dec. 19, 2014 - Seeking Alpha
Cramer: ‘Downside’ to Biotech as ImmunoGen Stock Cut in Half 10:46 a.m. Dec. 19, 2014 - TheStreet.com
Critical Alerts For Invensense, FireEye, General Electric, Twitter and Celgene Released By InvestorsObserver 9:31 a.m. Dec. 22, 2014 - PR Newswire - PRF
Scanning Biotech Equities -- Celgene, Novavax, Amarin, Immunomedics, and Aeterna Zentaris 8:40 a.m. Dec. 17, 2014 - PR Newswire - PRF
Data Presented on REVLIMID® (lenalidomide) Compared with Investigators’ Choice in Relapsed/Refractory Diffuse Large B-Cell Lymphoma 8:34 p.m. Dec. 8, 2014 - BusinessWire - BZX
Additional Analyses of High-Risk Patients from Phase III Study (AML-001) OF Vidaza® (Azacitidine for Injection) in Acute Myeloid Leukemia Presented at ASH 8:33 p.m. Dec. 8, 2014 - BusinessWire - BZX
REVLIMID® (Lenalidomide) Single-Agent and Combination Studies in Mantle Cell Lymphoma (MCL) Presented at ASH 8:33 p.m. Dec. 8, 2014 - BusinessWire - BZX
New Data in Myelodysplastic Syndromes Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition 2:00 p.m. Dec. 8, 2014 - BusinessWire - BZX
Results from Phase III Study of REVLIMID® (Lenalidomide) Demonstrating Improved Transfusion Independence in Patients with Rare Blood Cancer, Non-Del-5Q Myelodysplastic Syndromes (MDS), Presented at ASH 1:49 p.m. Dec. 8, 2014 - BusinessWire - BZX
Age, Renal Impairment and Depth of Response Analyses of the FirstTM (MM-020/IFM 07-01)Study of Continuous REVLIMID® (lenalidomide) Plus Low-Dose dexamethasone in Newly-Diagnosed Multiple Myeloma Presented at ASH 9:58 p.m. Dec. 7, 2014 - BusinessWire - BZX
Critical Alerts For Noodles & Company, Goldcorp, YY, Celgene and LinkedIn Released By InvestorsObserver 9:31 a.m. Dec. 2, 2014 - PR Newswire - PRF
Celgene Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Corporation 4:30 p.m. Dec. 1, 2014 - BusinessWire - BZX
Celgene Receives Positive CHMP Opinion for OTEZLA® (apremilast), the First Oral PDE4 Inhibitor for the Treatment of Patients with Psoriasis and Psoriatic Arthritis 6:00 a.m. Nov. 21, 2014 - BusinessWire - BZX
Chef Michael Ferraro, the Pancreatic Cancer Action Network and Meals to Heal Team up with Celgene to Address Nutritional Needs and Challenges Faced by Pancreatic Cancer Patients and Caregivers 8:00 a.m. Nov. 20, 2014 - BusinessWire - BZX
UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Increases CD4 Counts in People Living With HIV 4:29 p.m. Nov. 19, 2014 - Marketwired
Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Counts in People Living With HIV 3:35 p.m. Nov. 19, 2014 - Marketwired
Oral OTEZLA® (Apremilast) Showed Sustained Clinical Response over Two Years in Patients with Active Psoriatic Arthritis 7:30 a.m. Nov. 18, 2014 - BusinessWire - BZX
Moffitt Cancer Center Announces Development of Experimental Treatment for Myelodysplastic Syndromes, Autoimmune Diseases 9:03 a.m. Nov. 17, 2014 - BusinessWire - BZX
Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene 9:10 a.m. Nov. 14, 2014 - PR Newswire - PRF
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo 8:50 a.m. Nov. 10, 2014 - PR Newswire - PRF
Critical Alerts For Alibaba, Bloomin' Brands, VoxelJet, 51job and Celgene Released By InvestorsObserver 9:31 a.m. Nov. 5, 2014 - PR Newswire - PRF
Celgene Corporation to Webcast at Upcoming Investor Conferences and Medical Congress 8:30 a.m. Oct. 31, 2014 - BusinessWire - BZX
